NASDAQ:INCR InterCure (INCR) Stock Price, News & Analysis → The AI Bottleneck No One is Talking About (From The Bull Report) (Ad) Free INCR Stock Alerts $1.99 +0.14 (+7.57%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$1.92▼$2.0650-Day Range$1.18▼$2.0352-Week Range$0.99▼$2.87Volume83,331 shsAverage Volume79,942 shsMarket Capitalization$90.68 millionP/E Ratio15.31Dividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get InterCure alerts: Email Address InterCure MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside151.3% Upside$5.00 Price TargetShort InterestHealthy0.51% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.97 out of 5 starsMedical Sector420th out of 947 stocksPharmaceutical Preparations Industry197th out of 435 stocks 3.5 Analyst's Opinion Consensus RatingInterCure has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, InterCure has a forecasted upside of 151.3% from its current price of $1.99.Amount of Analyst CoverageInterCure has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.51% of the float of InterCure has been sold short.Short Interest Ratio / Days to CoverInterCure has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in InterCure has recently increased by 3.59%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldInterCure does not currently pay a dividend.Dividend GrowthInterCure does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INCR. Previous Next 3.3 News and Social Media Coverage News SentimentInterCure has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for InterCure this week, compared to 0 articles on an average week.Search Interest1 people have searched for INCR on MarketBeat in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, InterCure insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.24% of the stock of InterCure is held by insiders. Previous Next 1.9 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of InterCure is 15.31, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 152.48.Price to Earnings Ratio vs. SectorThe P/E ratio of InterCure is 15.31, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 225.29.Price to Book Value per Share RatioInterCure has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Prosper Trading AcademyDid you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:Click Here To Get Your Free Copy About InterCure Stock (NASDAQ:INCR)InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.Read More INCR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INCR Stock News HeadlinesMarch 12, 2024 | americanbankingnews.comInterCure (NASDAQ:INCR) Trading Down 2.7%February 23, 2024 | businesswire.comPESG Industry Updates: Germany's Cannabis Act and Its Impact on the Medical Cannabis LandscapeMarch 19, 2024 | Porter & Company (Ad)Urgent new message from Porter StansberryI’ve been in the financial markets for close to three decades… Yet, I’ve never seen an opportunity that’s so urgent, so critical, and yet so overlooked than what is unfolding right now. You see, in one corner of the markets a financial anomaly has emerged that promises to be the single most important story of 2024.February 13, 2024 | finance.yahoo.comInterCure Provides an Update Regarding Nir Oz FacilityFebruary 13, 2024 | globenewswire.comInterCure Provides an Update Regarding Nir Oz FacilityJanuary 31, 2024 | msn.comInterCure to buy Isreal-based Leon cannabis pharmacy chainJanuary 18, 2024 | investing.comIntrakat Technikon Kai Energeiakon Ergon AE (INCr)January 10, 2024 | msn.comWKEY, INCR and ZJYL are among pre market gainersMarch 19, 2024 | Porter & Company (Ad)Urgent new message from Porter StansberryI’ve been in the financial markets for close to three decades… Yet, I’ve never seen an opportunity that’s so urgent, so critical, and yet so overlooked than what is unfolding right now. You see, in one corner of the markets a financial anomaly has emerged that promises to be the single most important story of 2024.January 9, 2024 | benzinga.comIntercure Stock (NASDAQ:INCR) Dividends: History, Yield and DatesJanuary 6, 2024 | investing.comINCR_t3 Historical DataNovember 9, 2023 | morningstar.comIntercure Ltd INCROctober 17, 2023 | msn.comInterCure says one of its sites designated as closed military area by Israeli authoritiesSeptember 1, 2023 | benzinga.comCanndoc Reports Record Revenue Amid Cannabis Market TurmoilAugust 22, 2023 | theglobeandmail.comClosing Bell: Intercure Ltd up on Monday (INCR-U)August 19, 2023 | theglobeandmail.comul: Bottom 25 Performing Stocks Year-to-Date on TSX (INCR-U)August 3, 2023 | msn.comInterCure: Leader In Israel's Growing Medical Cannabis MarketJuly 23, 2023 | theglobeandmail.comIntercure: Top 10 Undervalued Micro Cap Stocks on TSX (INCR-U)July 10, 2023 | financialpost.comInterCure Ltd. Announces Proposed Voluntary Delisting from the Toronto Stock Exchange and shall continue to be listed on the NASDAQ and TASEMay 16, 2023 | finanznachrichten.deInterCure Ltd.: InterCure Announces Record Breaking First Quarter Revenues with 22% growth YOYMay 16, 2023 | msn.comInterCure Stock Trading Lower On Q1 Revenue Growth Of 22%, Here Are The DetailsMay 15, 2023 | benzinga.comInterCure Announces Record Breaking First Quarter Revenues with 22% growth YOYApril 27, 2023 | theglobeandmail.comClosing Bell: Intercure Ltd down on Monday (INCR-U)April 26, 2023 | theglobeandmail.comClosing Bell: Intercure Ltd flat on Monday (INCR-U)April 25, 2023 | finance.yahoo.comInterCure Informs That A Lawsuit Was Filed Against the Company by Minority Shareholders of Its SubsidiaryApril 24, 2023 | finance.yahoo.comInterCure Informs That An Application To Approve a Class Action Against 26 Cannabis Companies in Israel, Including InterCure, Was Filed to The Court In IsraelApril 20, 2023 | finance.yahoo.comInterCure Ltd. Partners with TYSON 2.0 in Israel, Australia, United Kingdom, Germany and Other EU CountriesSee More Headlines Receive INCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InterCure and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/18/2024Next Earnings (Estimated)3/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:INCR CUSIPN/A CIK1857030 Webwww.intercure.co Phone972774605012FaxN/AEmployees370Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+151.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$0.13 Trailing P/E Ratio15.31 Forward P/E RatioN/A P/E GrowthN/ANet Income$13.36 million Net Margins4.28% Pretax MarginN/A Return on Equity3.37% Return on Assets1.98% Debt Debt-to-Equity Ratio0.20 Current Ratio1.90 Quick Ratio1.21 Sales & Book Value Annual Sales$115.83 million Price / Sales0.78 Cash Flow$0.45 per share Price / Cash Flow4.44 Book Value$3.64 per share Price / Book0.55Miscellaneous Outstanding Shares45,570,000Free Float45,464,000Market Cap$90.68 million OptionableOptionable Beta1.62 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Alexander Rabinovich (Age 53)CEO & Director Comp: $500kMr. Amos Cohen (Age 45)Chief Financial Officer Comp: $848kEinat ZehaviVice President of SalesMr. Omri BatzirCorporate ControllerKey CompetitorsLantern PharmaNASDAQ:LTRNOncolytics BiotechNASDAQ:ONCYCue BiopharmaNASDAQ:CUEBioLineRxNASDAQ:BLRXBioXcel TherapeuticsNASDAQ:BTAIView All CompetitorsInstitutional OwnershipCitadel Advisors LLCSold 1,600 shares on 2/15/2024Ownership: 0.000%Simplex Trading LLCBought 100 shares on 2/2/2024Ownership: 0.000%Mirae Asset Global Investments Co. Ltd.Bought 271,080 shares on 1/24/2024Ownership: 0.000%View All Institutional Transactions INCR Stock Analysis - Frequently Asked Questions Should I buy or sell InterCure stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InterCure in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" INCR shares. View INCR analyst ratings or view top-rated stocks. What is InterCure's stock price target for 2024? 1 equities research analysts have issued twelve-month price targets for InterCure's stock. Their INCR share price targets range from $5.00 to $5.00. On average, they anticipate the company's share price to reach $5.00 in the next year. This suggests a possible upside of 151.3% from the stock's current price. View analysts price targets for INCR or view top-rated stocks among Wall Street analysts. How have INCR shares performed in 2024? InterCure's stock was trading at $1.2898 on January 1st, 2024. Since then, INCR stock has increased by 54.3% and is now trading at $1.99. View the best growth stocks for 2024 here. When is InterCure's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024. View our INCR earnings forecast. Who are InterCure's major shareholders? InterCure's stock is owned by a variety of retail and institutional investors. Top institutional investors include Mirae Asset Global Investments Co. Ltd. (0.00%), Citadel Advisors LLC (0.00%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of InterCure? Shares of INCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INCR) was last updated on 3/19/2024 by MarketBeat.com Staff From Our Partners8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe world’s greatest investmentPorter & CompanyStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InterCure Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.